

Attorney Docket No.: P-408 (TI-0013)  
Inventors: Taylor et al.  
Serial No.: 09/802,466  
Filing Date: March 9, 2001  
Page 2

**In the Specification:**

Please replace the paragraph beginning on page 23, line 24 with the following rewritten paragraph:

-- An important aspect of the present invention concerns the cross-sectional dimension of the separation column 78. ~~Fig. 4~~ Figure 14 is a partially exploded representation of the physical structure of a representative separation column. The column comprises a cylinder or tube 334 with external ferrule 335 on both ends. The tube has internal diameter (ID) as shown at 333 and is filled with separation media 336. A porous frit 338 is held against the upper surface of the separation media by the end fitting 340. The end fitting 340 receives frit 338 and holds the frit against the end of the tube 334. The internally threaded nut 342 receives the externally threaded fitting 340 in a threaded engagement. The fitting 340 has an internally threaded end receptor 346 for receiving a capillary tubing end coupler (not shown).--

Please replace the paragraph beginning on page 30, line 20 with the following rewritten paragraph:

-- Considering mixtures containing 0%, 5%, and 10% acetonitrile, the results (FIG. 27) indicated that in 30 days,

Attorney Docket No.: **P-408 (TI-0013)**  
Inventors: **Taylor et al.**  
Serial No.: **09/802,466**  
Filing Date: **March 9, 2001**  
Page 3

the mRNA had degraded by a large amount (more than 50%) regardless of the presence of acetonitrile in the starting solutions both for mixtures at room temperature and for those stored at -20°C. Similar experiments, but including the counterion agent TEAA were conducted, and showed the same results as with ~~acetonitrile~~ acetonitrile alone.--